We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
AbbVie has formed an alliance with Scripps Research’s non-profit drug discovery unit Calibr to develop next-generation T-cell therapies that are aimed at targeting various cancers, including solid tumours.